FDA panel sets review date for Thoratec's LVAS (left ventricular assist system):
This article was originally published in Clinica
Executive Summary
An advisory panel to the US FDA is scheduled to review Thoratec's application to expand the intended use of its HeartMate VE LVAS (left ventricular assist system) on March 4. The company's premarket approval supplement, which is based on the results of Thoratec's REMATCH trial (see Clinica, No 985, p 17), is seeking clearance to use the device for long-term support in end-stage heart failure patients who are not eligible for heart transplantation. The device is currently approved for use as a bridge to heart transplant, says the Pleasanton, California firm.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.